0001209191-21-046028.txt : 20210708
0001209191-21-046028.hdr.sgml : 20210708
20210708181557
ACCESSION NUMBER: 0001209191-21-046028
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210706
FILED AS OF DATE: 20210708
DATE AS OF CHANGE: 20210708
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hardie Robert D.
CENTRAL INDEX KEY: 0001804350
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40551
FILM NUMBER: 211081202
MAIL ADDRESS:
STREET 1: 210 RIDGE MCINTIRE ROAD, SUITE 350
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22903
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001576885
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 364108129
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4435 NORTH FIRST STREET, SUITE 360
CITY: LIVERMORE
STATE: CA
ZIP: 94551
BUSINESS PHONE: 925-368-8508
MAIL ADDRESS:
STREET 1: 4435 NORTH FIRST STREET, SUITE 360
CITY: LIVERMORE
STATE: CA
ZIP: 94551
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-06
1
0001576885
Acumen Pharmaceuticals, Inc.
ABOS
0001804350
Hardie Robert D.
C/O ACUMEN PHARMACEUTICALS, INC.
427 PARK STREET
CHARLOTTESVILLE
VA
22902
0
0
1
0
Common Stock
2021-07-06
4
C
0
2950484
A
3040193
I
See footnote
Common Stock
2021-07-06
4
P
0
312500
16.00
A
3352693
I
See footnote
Common Stock
2021-07-06
4
C
0
657985
A
657985
I
See footnote
Series A-1 Preferred Stock
2021-07-06
4
C
0
1634515
0.00
D
Common Stock
1634515
0
I
See footnote
Series B Preferred Stock
2021-07-06
4
C
0
1315969
0.00
D
Common Stock
1315969
0
I
See footnote
Series B Preferred Stock
2021-07-06
4
C
0
657985
0.00
D
Common Stock
657985
0
I
See footnote
On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred
Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of
the Issuer's common stock. The shares had no expiration date.
The securities are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust.
The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC, the
manager of BKB, and has shared voting and investment power with respect to the shares held by BKB.
/s/ Katherine Denby, Attorney-in-Fact
2021-07-08